A citation-based method for searching scientific literature

Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit, Byoung C Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young-Chul Kim, Christos S Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E Gray, Luis Paz-Ares, Javier de Castro Carpeño, Corinne Faivre-Finn, Martin Reck, Johan Vansteenkiste, David R Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A Dennis, Mustafa Özgüroğlu. N Engl J Med 2018
Times Cited: 1141







List of co-cited articles
591 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2017
40

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
Jhanelle E Gray, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho,[...]. J Thorac Oncol 2020
157
19

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Jeffrey D Bradley, Rebecca Paulus, Ritsuko Komaki, Gregory Masters, George Blumenschein, Steven Schild, Jeffrey Bogart, Chen Hu, Kenneth Forster, Anthony Magliocco,[...]. Lancet Oncol 2015
15

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
15

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
15

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
14

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
14

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Jeffrey D Bradley, Chen Hu, Ritsuko R Komaki, Gregory A Masters, George R Blumenschein, Steven E Schild, Jeffrey A Bogart, Kenneth M Forster, Anthony M Magliocco, Vivek S Kavadi,[...]. J Clin Oncol 2020
110
14

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
13

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
Simon J Dovedi, Amy L Adlard, Grazyna Lipowska-Bhalla, Conor McKenna, Sherrie Jones, Eleanor J Cheadle, Ian J Stratford, Edmund Poon, Michelle Morrow, Ross Stewart,[...]. Cancer Res 2014
608
13

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
12

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Willemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari, Vincent van der Noort, Jeltje F de Vries, Joachim G J V Aerts, Daphne W Dumoulin, Idris Bahce, Anna-Larissa N Niemeijer, Adrianus J de Langen,[...]. JAMA Oncol 2019
269
12

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
Claire Vanpouille-Box, Amandine Alard, Molykutty J Aryankalayil, Yasmeen Sarfraz, Julie M Diamond, Robert J Schneider, Giorgio Inghirami, C Norman Coleman, Silvia C Formenti, Sandra Demaria. Nat Commun 2017
681
12

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
Anne Aupérin, Cecile Le Péchoux, Estelle Rolland, Walter J Curran, Kiyoyuki Furuse, Pierre Fournel, Jose Belderbos, Gerald Clamon, Hakki Cuneyt Ulutin, Rebecca Paulus,[...]. J Clin Oncol 2010
11

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
Liufu Deng, Hua Liang, Byron Burnette, Michael Beckett, Thomas Darga, Ralph R Weichselbaum, Yang-Xin Fu. J Clin Invest 2014
11

Combining radiotherapy and cancer immunotherapy: a paradigm shift.
Silvia C Formenti, Sandra Demaria. J Natl Cancer Inst 2013
614
10

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
10

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
742
10

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
10

Therapeutic management options for stage III non-small cell lung cancer.
Stephanie M Yoon, Talha Shaikh, Mark Hallman. World J Clin Oncol 2017
107
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
9

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
L Paz-Ares, A Spira, D Raben, D Planchard, B C Cho, M Özgüroğlu, D Daniel, A Villegas, D Vicente, R Hui,[...]. Ann Oncol 2020
44
20

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Suresh Senan, Anthony Brade, Lu-Hua Wang, Johan Vansteenkiste, Shaker Dakhil, Bonne Biesma, Maite Martinez Aguillo, Joachim Aerts, Ramaswamy Govindan, Belén Rubio-Viqueira,[...]. J Clin Oncol 2016
224
9

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
9

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Silvia C Formenti, Nils-Petter Rudqvist, Encouse Golden, Benjamin Cooper, Erik Wennerberg, Claire Lhuillier, Claire Vanpouille-Box, Kent Friedman, Lucas Ferrari de Andrade, Kai W Wucherpfennig,[...]. Nat Med 2018
301
9

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Liufu Deng, Hua Liang, Meng Xu, Xuanming Yang, Byron Burnette, Ainhoa Arina, Xiao-Dong Li, Helena Mauceri, Michael Beckett, Thomas Darga,[...]. Immunity 2014
849
9

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
8

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
Jason J Luke, Jeffrey M Lemons, Theodore G Karrison, Sean P Pitroda, James M Melotek, Yuanyuan Zha, Hania A Al-Hallaq, Ainhoa Arina, Nikolai N Khodarev, Linda Janisch,[...]. J Clin Oncol 2018
257
8

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P E Postmus, K M Kerr, M Oudkerk, S Senan, D A Waller, J Vansteenkiste, C Escriu, S Peters. Ann Oncol 2017
634
8

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J Hochmair, Florian Huemer, György Losonczy, Melissa L Johnson, Makoto Nishio,[...]. N Engl J Med 2018
8

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. J Clin Oncol 2019
520
8

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
8

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
Eric A Reits, James W Hodge, Carla A Herberts, Tom A Groothuis, Mala Chakraborty, Elizabeth K Wansley, Kevin Camphausen, Rosalie M Luiten, Arnold H de Ru, Joost Neijssen,[...]. J Exp Med 2006
974
8

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh, François Ghiringhelli, Antoine Tesniere, Michel Obeid, Carla Ortiz, Alfredo Criollo, Grégoire Mignot, M Chiara Maiuri, Evelyn Ullrich, Patrick Saulnier,[...]. Nat Med 2007
7

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Stephen G Chun, Chen Hu, Hak Choy, Ritsuko U Komaki, Robert D Timmerman, Steven E Schild, Jeffrey A Bogart, Michael C Dobelbower, Walter Bosch, James M Galvin,[...]. J Clin Oncol 2017
327
7

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
7

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Luis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji,[...]. Lancet 2019
460
7

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, James Ranger-Moore, Malinka Jansson, Karina Kulangara, William Richardson, Penny Towne, Debra Hanks, Bharathi Vennapusa,[...]. J Thorac Oncol 2017
767
7

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, Kellie N Smith, Valsamo Anagnostou, Tricia R Cottrell, Matthew D Hellmann, Marianna Zahurak, Stephen C Yang, David R Jones, Stephen Broderick,[...]. N Engl J Med 2018
733
7

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
S Peters, E Felip, U Dafni, C Belka, M Guckenberger, A Irigoyen, E Nadal, A Becker, H Vees, M Pless,[...]. Lung Cancer 2019
61
11

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.
M Zahidunnabi Dewan, Ashley E Galloway, Noriko Kawashima, J Keith Dewyngaert, James S Babb, Silvia C Formenti, Sandra Demaria. Clin Cancer Res 2009
918
7

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, Amit Maity, Ramesh Rengan, Kristen E Pauken, Erietta Stelekati, Joseph L Benci, Bihui Xu, Hannah Dada, Pamela M Odorizzi,[...]. Nature 2015
7

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park. Lung Cancer 2020
28
25

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
6

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K Choueiri, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Saby George,[...]. N Engl J Med 2018
6

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
6

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
6

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, Lecia V Sequist, Xiujun Fu, Christopher G Azzoli, Zofia Piotrowska, Tiffany G Huynh, Ling Zhao, Linnea Fulton, Katherine R Schultz,[...]. Clin Cancer Res 2016
618
6

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland,[...]. Lancet 2019
596
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.